Stress exacerbates disease, and understanding its molecular mechanisms is crucial to the development of novel therapeutic interventions to combat stress-related disorders. The driver of the stress response in the hypothalamic-pituitary-adrenal axis (HPA) is corticotropin-releasing hormone (CRH), a neuropeptide synthesized in the paraventricular nucleus of the hypothalamus. Evidence supports that CRH expression is epigenetically modified at the molecular level by environmental stimuli, causing changes in the stress response. This effect is mediated by a concert of factors that translate environmental change into alterations in gene expression. An important regulator and epigenetic modulator of CRH expression is neuron-restrictive silencing factor (NRSF). Previously, our lab identified numerous splice variants of NRSF that are specific to humans and predictive of differential regulatory effects of NRSF variants on targeted gene expression. The human cell line BeWo has endogenous CRH and NRSF expression providing an in vitro model system. Here, we show that manipulation of NRSF expression through siRNA technology, overexpression by plasmid vectors, and direct cAMP induction that CRH expression is linked to changes in NRSF expression. Accordingly, this epigenetic regulatory pathway in humans might be a critical mechanism involved in the regulation of the stress response.

Keywords:
Corticotropin-releasing hormone, Neuron-restrictive silencing factor, Stress regulation
1.
Chrousos GP: Stress and disorders of the stress system. Nat Rev Endocrinol 2009; 5: 374.
2.
McEwen BS: In pursuit of resilience: stress, epigenetics, and brain plasticity. Ann NY Acad Sci 2016; 1373: 56–64.
3.
De Souza EB, Battaglia G: Corticotropin-releasing hormone (CRH) receptors in brain. Adv Exp Med Biol 1988; 245: 123–136.
4.
Smith SM, Vale WW: The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci 2006; 8: 383–395.
5.
Grammatopoulos DK: Insights into mechanisms of corticotropin-releasing hormone receptor signal transduction. Br J Pharmacol 2012; 166: 85–97.
6.
Hiroi N, Wong ML, Licinio J, et al: Expression of corticotropin releasing hormone receptors type I and type II mRNA in suicide victims and controls. Mol Psychiatry 2001; 6: 540–546.
7.
Dedic N, Deussing AC and JM: The CRF family of neuropeptides and their receptors – mediators of the central stress response. Curr Mol Pharmacol 2017; 10: 1–28.
8.
Uhlen M, Fagerberg L, Hallstrom BM, et al: Tissue-based map of the human proteome. Science 2015; 347: 1260419.
9.
Gallagher JP, Orozco-Cabal LF, Liu J, Shinnick-Gallagher P: Synaptic physiology of central CRH system. Eur J Pharmacol 2008; 583: 215–225.
10.
Roozendaal B, Brunson KL, Holloway BL, McGaugh JL, Baram TZ: Involvement of stress-released corticotropin-releasing hormone in the basolateral amygdala in regulating memory consolidation. Proc Natl Acad Sci USA 2002; 99: 13908–13913.
11.
Steckler T, Holsboer F: Corticotropin-releasing hormone receptor subtypes and emotion. Biol Psychiatry 1999; 46: 1480–1508.
12.
Kano M, Muratsubaki T, Van Oudenhove L, et al: Altered brain and gut responses to corticotropin-releasing hormone (CRH) in patients with irritable bowel syndrome. Sci Rep 2017; 7.
13.
Stankiewicz AM, Swiergiel AH, Lisowski P: Epigenetics of stress adaptations in the brain. Brain Res Bull 2013; 98: 76–92.
14.
Elliott E, Ezra-Nevo G, Regev L, Neufeld-Cohen A, Chen A: Resilience to social stress coincides with functional DNA methylation of the Crf gene in adult mice. Nat Neurosci 2010; 13: 1351–1353.
15.
Sterrenburg L, Gaszner B, Boerrigter J, et al: Sex-dependent and differential responses to acute restraint stress of corticotropin-releasing factor-producing neurons in the rat paraventricular nucleus, central amygdala, and bed nucleus of the stria terminalis. J Neurosci Res 2012; 90: 179–192.
16.
Chen J, Evans AN, Liu Y, Honda M, Saavedra JM, Aguilera G: Maternal deprivation in rats is associated with corticotrophin-releasing hormone (CRH) promoter hypomethylation and enhances CRH transcriptional responses to stress in adulthood. J Neuroendocrinol 2012; 24: 1055–1064.
17.
Mueller BR, Bale TL: Sex-specific programming of offspring emotionality after stress early in pregnancy. J Neurosci 2008; 28: 9055–9065.
18.
Chen GL, Miller GM: Extensive alternative splicing of the repressor element silencing transcription factor linked to cancer. PLoS One 2013; 8:e62217.
19.
Otto SJ, McCorkle SR, Hover J, et al: A new binding motif for the transcriptional repressor REST uncovers large gene networks devoted to neuronal functions. J Neurosci 2007; 27: 6729–6739.
20.
Schoenherr CJ, Paquette AJ, Anderson DJ: Identification of potential target genes for the neuron-restrictive silencer factor. Proc Natl Acad Sci USA 1996; 93: 9881–9886.
21.
Satoh JI, Kawana N, Yamamoto Y: ChiP-seq data mining: remarkable differences in NRSF/REST target genes between human ESC and ESC-derived neurons. Bioinform Biol Insights 2013; 7: 357–368.
22.
Seth KA, Majzoub JA: Repressor element silencing transcription factor/neuron-restrictive silencing factor (REST/NRSF) can act as an enhancer as well as a repressor of corticotropin-releasing hormone gene transcription. J Biol Chem 2001; 276: 13917–13923.
23.
Korosi A, Shanabrough M, McClelland S, et al: Early-life experience reduces excitation to stress-responsive hypothalamic neurons and reprograms the expression of corticotropin-releasing hormone. J Neurosci 2010; 30: 703–713.
24.
Singh-Taylor A, Molet J, Jiang S, et al: NRSF-dependent epigenetic mechanisms contribute to programming of stress-sensitive neurons by neonatal experience, promoting resilience. Mol Psychiatry 2018; 23: 648–657.
25.
Singh-Taylor A, Molet J, Jiang S, et al: Early-life experience reprograms stress-sensitive neurons and influences adult phenotype via NRSF/REST-dependent epigenetic mechanisms. Neuropsychopharmacology 2015; 40: S477.
26.
Mou H, Zhao X: NRSF and CCR5 established neuron-glia communication during acute and chronic stresses. J Drug Metab Toxicol 2016; 7: 1–8.
27.
Uchida S, Hara K, Kobayashi A, et al: Early life stress enhances behavioral vulnerability to stress through the activation of REST4-mediated gene transcription in the medial prefrontal cortex of rodents. J Neurosci 2010; 30: 15007–15018.
28.
Otsuki K, Uchida S, Wakabayashi Y, et al: Aberrant REST-mediated transcriptional regulation in major depressive disorder. J Psychiatr Res 2010; 44: 378–384.
29.
Pan X, Bowman M, Scott RJ, et al: Methylation of the corticotropin releasing hormone gene promoter in BeWo Cells: relationship to gene activity. Int J Endocrinol 2015; 2015: 861302.
30.
Chen GL, Miller GM: Tryptophan hydroxylase-2: an emerging therapeutic target for stress disorders. Biochem Pharmacol 2013; 85: 1227–1233.
31.
Lonsdale J, Thomas J, Salvatore M, et al: The genotype-tissue expression (GTEx) project. Nat Genet 2013; 45: 580–585.
32.
Tang L, Nogales E, Ciferri C: Structure and function of SWI/SNF chromatin remodeling complexes and mechanistic implications for transcription. Prog Biophys Mol Biol 2010; 102: 122–128.
33.
Watanabe H, Mizutani T, Haraguchi T, et al: SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines. Oncogene 2006; 25: 470–479.
34.
Ravache M, Weber C, Mérienne K, Trottier Y: Transcriptional activation of REST by Sp1 in Huntington’s disease models. PLoS One 2010; 5.
35.
Zhang F, Hu Y, Huang P, Toleman CA, Paterson AJ, Kudlow JE: Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J Biol Chem 2007; 282: 22460–22471.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.